What Telix’s EANM 2026 presentations reveal about its theranostics pipeline
Telix will present 20 research abstracts at EANM 2026, including updates on pivotal brain and kidney cancer therapy trials, interim prostate cancer treatment findings and Phase 3 imaging data from China. The congress showcases a broad radiopharmaceutical pipeline, but most investigational programmes have not yet reported registrational efficacy results.
